长春瑞滨加异环磷酰胺加顺铂治疗晚期非小细胞肺癌98例临床疗效观察

目的观察长春瑞滨(NVB)、异环磷酰胺(IFO)、顺铂(PDD)三药联合(NIP)治疗晚期非小细胞肺癌的疗效和毒性.方法共收治ⅢB～Ⅳ期非小细胞肺癌98例,其中鳞癌51例,腺癌42例,大细胞癌5例.ⅢB期59例,Ⅳ期39例.初治71例,复治27例.方案:NVB 25 mg/m2静滴,第1,8天;IFO 1.5 g/m2,静滴,第1～3天;PDD 30 mg/m2,静滴,第1～3天.4周为一周期.结果 CR 1例,PR 44例,NC 45例,PD 8例,总有效率(CR PR)为45.9%.中位缓解期8个月,中位生存期11个月,1年生存率为48.0%.骨髓抑制为剂量限制性毒性,其中Ⅲ～Ⅳ度占40.8%.结论 NIP方案是治疗晚期非小细胞肺癌有效且安全的方案.     

SURGERY OF PERIURETERIC OBSTRUCTION IN 101 CHILDREN OVER ONE YEAR OF AGE

One hundred and one children over 1 year of age have had surgery for pelviureteric obstruction over an 11 year period. The common clinical features were abdominal pain, urinary infection or haematuria, but number presented as an incidental finding. Less commonly, the patients presented with an abdominal mass or with hypertension. The diagnosis was usually made on intravenous pyelography (IVP) but in the latter part of the series, renal nuclide scan (RNS) and ultrasonography (US) were preferred. Ninety–three patients had unilateral pyeloplasty, three had bilateral pyeloplasty and five had nephrectomy or heminephrectomy. Whereas initially nephrostomy drainage was used in the majority of patients after pyeloplasty, trend away from nephrostomy evolved in the latter part of the series. With experience, the incidence of postoperative complications was also reduced and there was reduction in the period of hospitalization. Clinical results were consistently satisfactory. Postoperative assessment after pyeloplasty was made by IVP and/or RNS and also US. A review of these investigations showed that RNS provided more factual information of the result when compared with the IVP.     

18F-FDG与18F-FLT PET/CT延迟显像对肺结节诊断效能的评价

目的 通过对多中心、前瞻性研究中接受了18F-脱氧葡萄糖(FDG)与18F-脱氧胸腺嘧啶核苷(FLT)延迟显像病例的分析,探讨18F-FDG与18F-FLT延迟显像对肺结节诊断的效能.方法 6个PET/CT中心,从2006年1月至2007年6月,按照统一标准,采用同机型、同一扫描条件,开展了肺结节样病变18F-FLT和18F-FDG PET/CT显像的多中心临床研究.在经确诊的55例病例中,25例患者进行了18F-FLT显像和延迟显像,34例患者进行了18F-FDG延迟显像.按常规计算延迟显像时病灶最大标准摄取值(SUVmax)及与早期显像时SUVmax相比的变化率(△SUVmax).对照临床确诊结果分析其诊断效能.采用SPSS11.0软件进行统计学处理.结果 18F-FDG延迟显像患者中,6例肺癌中5例、12例结核中9例、16例炎症或其他良性结节中9例的SUVmax较早期相升高.18F-FLT延迟显像组中,7例肺癌中3例、8例结核中3例和10例其他良性病灶中2例的SUVmax上升.经分组统计分析,不同疾病组间18F-FDG延迟显像SUVmax和△SUVmax差异无统计学意义;18F-FLT延迟显像SUVmax和△SUVmax组间差异也无统计学意义.无论18F-FDG还是18F-FLT,延迟显像的诊断效能均不如早期相.无论早期还是延迟显像,单独18F-FDG或18F-FLT显像的诊断效能均不如二者联合应用.结论 18F-FDG和18F-FLT延迟显像的SUVmax变化规律性不强,不宜单独应用于肺结节的鉴别诊断.     

Menghini针在经皮肺活检中的应用

本文介绍了44例经皮肺活检的经验,40例诊断正确,占90.9%;气胸发生率6.8%,作者认为 Menghini 针具有操作简单,无气栓发生,更换注射器方便等优点。同时对导向的选用及穿剌方法的改进也做了介绍。     

经腹及经阴道B超监测卵泡发育的评估

应用经腹及经阴道B超对68名不孕症妇女,139个月经周期进行卵泡发育及排卵监测。卵泡检出率TAUS为90.6％,TVUS为98.0％,显著高于前者,P<0.05。成熟卵泡特征影象(卵丘等)在TVUS显象率较高。TVUS监测卵泡发育更实用可靠。     

电视纵隔镜手术在肺癌分期中的应用价值

背景与目的　随着新辅助治疗方案的提出,以及人们逐渐认识到CT和PET等检查在肺癌分期中的局限性,纵隔镜手术在肺癌分期中的价值日益受到人们的重视。本研究旨在探讨电视纵隔镜手术在肺癌纵隔淋巴结分期中的应用价值。方法　回顾性总结2001年9月至2004年6月60例经电视纵隔镜检查的肺癌患者的临床资料,其中颈部电视纵隔镜手术52例,胸骨旁电视纵隔镜手术2 例,颈部加胸骨旁电视纵隔镜手术6例。术前所有患者胸部CT均发现纵隔淋巴结肿大(直径大于1.0 cm)。结果　本组60 例患者,经电视纵隔镜检查证实纵隔淋巴结转移(阳性)者42例,未见纵隔淋巴结转移(阴性)者18例。纵隔淋巴结阳性者放弃手术,予以化疗;阴性者中转开胸行肺叶切除或肺楔形切除加纵隔淋巴结清扫,术后病理证实17 例纵隔淋巴结未见转移,1例隆凸后淋巴结可见癌转移(电视纵隔镜检查假阴性)。电视纵隔镜手术敏感性、特异性和准确性分别为97.7%、100%和98.3%。本组术中发生无名动脉撕裂1 例,并发症发生率为1.7%(1/60)。无围手术期死亡。结论　电视纵隔镜手术安全、可靠,可作为明确肺癌分期的常规方法。     

Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer

BACKGROUND: High-intensity focused ultrasound (HIFU) is a minimally invasive technique used in achieve coagulation necrosis. We evaluated biochemical disease-free survival rates, predictors of clinical outcome and morbidity in patients with localized prostate cancer treated with HIFU. METHODS: A total of 181 consecutive patients underwent HIFU with the use of Sonablate (Focus Surgery, Indianapolis, IN, USA). Biochemical recurrence was defined according to the criteria recommended by the American Society for Therapeutic Radiology and Oncology Consensus Panel. The median age and pretreatment prostate-specific antigen (PSA) level were 70 years (range 44-88) and 9.76 ng/mL (range 3.39-89.60). A total of 95 patients (52%) were treated with neoadjuvant hormones. The median follow-up period for all patients was 18.0 months (range 4-68). RESULTS: The biochemical disease-free survival rates at 1, 3 and 5 years in all patients were 84%, 80% and 78%, respectively. The biochemical disease-free survival rates at 3 years for patients with pretreatment PSA less than 10 ng/mL, 10.01-20.0 ng/mL and more than 20.0 ng/mL were 94%, 75% and 35%, respectively (P<0.0001). Multivariate analysis identified pretreatment PSA (P<0.0001) as a independent predictor of relapse. CONCLUSION: High-intensity focused ultrasound therapy appears to be a safe and efficacious minimally invasive therapy for patients with localized prostate cancer, especially those with a pretreatment PSA level less than 20 ng/mL.